Diagnostic Accuracy of Sonazoid-Enhanced Ultrasonography for Detection of Liver Metastasis.

Q1 Medicine
Anas Elgenidy, Khaled Saad, Reda Ibrahim, Aya Sherif, Taher Elmozugi, Moaz Y Darwish, Mahmoud Abbas, Yousif A Othman, Abdelrahman Elshimy, Alyaa M Sheir, Dina H Khattab, Abdallah A Helal, Mario M Tawadros, Osama Abuel-Naga, Hazem I Abdel-Rahman, Doaa Ali Gamal, Amira Elhoufey, Hamad Ghaleb Dailah, Rami A Metwally, Noran ElBazzar, Hashem Abu Serhan
{"title":"Diagnostic Accuracy of Sonazoid-Enhanced Ultrasonography for Detection of Liver Metastasis.","authors":"Anas Elgenidy, Khaled Saad, Reda Ibrahim, Aya Sherif, Taher Elmozugi, Moaz Y Darwish, Mahmoud Abbas, Yousif A Othman, Abdelrahman Elshimy, Alyaa M Sheir, Dina H Khattab, Abdallah A Helal, Mario M Tawadros, Osama Abuel-Naga, Hazem I Abdel-Rahman, Doaa Ali Gamal, Amira Elhoufey, Hamad Ghaleb Dailah, Rami A Metwally, Noran ElBazzar, Hashem Abu Serhan","doi":"10.3390/medsci13020042","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the potential clinical role and reliability of Sonazoid-enhanced ultrasound (SEUS) as a diagnostic tool for liver metastatic lesions.</p><p><strong>Methods: </strong>An extensive literature search was conducted across five electronic databases, PubMed, Scopus, Embase, Cochrane Library, and Web of Science, from their inception up to January 2024 to identify all studies evaluating the use of Sonazoid-enhanced ultrasonography for detecting hepatic metastases. A meta-analysis was performed to assess diagnostic accuracy using the Meta-DiSc 2.0 software.</p><p><strong>Results: </strong>A total of 31 studies were included, 16 of which were eligible for meta-analysis and diagnostic test accuracy evaluation. A total of 13 studies in the meta-analysis evaluated the diagnostic accuracy of contrast-enhanced ultrasound (CEUS) for 1347 metastatic and 1565 non-metastatic liver lesions. The pooled sensitivity and specificity for CEUS were 0.88 (95% CI: 0.82-0.92) and 0.92 (95% CI: 0.84-0.96), respectively. The combined positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 11.89 (95% CI: 5.42-26.09), 0.12 (95% CI:0.08-0.19), and 91.99 (95% CI: 32.15-263.17), respectively. Additionally, four studies of the meta-analysis assessed the diagnostic performance of contrast-enhanced intraoperative sonography (CE-IOUS) in detecting 664 metastatic and 246 non-metastatic liver lesions. The pooled sensitivity and specificity for CE-IOUS were 0.93 (95% CI: 0.82-0.97) and 0.84 (95% CI: 0.65-0.93), respectively. The aggregated positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were calculated as 5.95 (95% CI: 2.32-15.25), 0.07 (95% CI: 0.02-0.24), and 77.68 (95% CI: 10.33-583.86), respectively.</p><p><strong>Conclusions: </strong>CE-IOUS and CEUS are reliable approaches for diagnosing liver metastatic lesions. CE-IOUS, in particular, exhibits higher accuracy in identifying liver metastatic lesions, indicating its potential effectiveness in clinical practice.</p>","PeriodicalId":74152,"journal":{"name":"Medical sciences (Basel, Switzerland)","volume":"13 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12015772/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical sciences (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/medsci13020042","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To evaluate the potential clinical role and reliability of Sonazoid-enhanced ultrasound (SEUS) as a diagnostic tool for liver metastatic lesions.

Methods: An extensive literature search was conducted across five electronic databases, PubMed, Scopus, Embase, Cochrane Library, and Web of Science, from their inception up to January 2024 to identify all studies evaluating the use of Sonazoid-enhanced ultrasonography for detecting hepatic metastases. A meta-analysis was performed to assess diagnostic accuracy using the Meta-DiSc 2.0 software.

Results: A total of 31 studies were included, 16 of which were eligible for meta-analysis and diagnostic test accuracy evaluation. A total of 13 studies in the meta-analysis evaluated the diagnostic accuracy of contrast-enhanced ultrasound (CEUS) for 1347 metastatic and 1565 non-metastatic liver lesions. The pooled sensitivity and specificity for CEUS were 0.88 (95% CI: 0.82-0.92) and 0.92 (95% CI: 0.84-0.96), respectively. The combined positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 11.89 (95% CI: 5.42-26.09), 0.12 (95% CI:0.08-0.19), and 91.99 (95% CI: 32.15-263.17), respectively. Additionally, four studies of the meta-analysis assessed the diagnostic performance of contrast-enhanced intraoperative sonography (CE-IOUS) in detecting 664 metastatic and 246 non-metastatic liver lesions. The pooled sensitivity and specificity for CE-IOUS were 0.93 (95% CI: 0.82-0.97) and 0.84 (95% CI: 0.65-0.93), respectively. The aggregated positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were calculated as 5.95 (95% CI: 2.32-15.25), 0.07 (95% CI: 0.02-0.24), and 77.68 (95% CI: 10.33-583.86), respectively.

Conclusions: CE-IOUS and CEUS are reliable approaches for diagnosing liver metastatic lesions. CE-IOUS, in particular, exhibits higher accuracy in identifying liver metastatic lesions, indicating its potential effectiveness in clinical practice.

索那唑类药物增强超声检查肝转移的诊断准确性。
目的:评价索那唑类药物增强超声(SEUS)作为肝转移性病变诊断工具的潜在临床作用和可靠性。方法:对5个电子数据库PubMed、Scopus、Embase、Cochrane Library和Web of Science进行了广泛的文献检索,从其成立到2024年1月,以确定所有评估使用索那唑类药物增强超声检查肝转移的研究。采用Meta-DiSc 2.0软件进行meta分析以评估诊断准确性。结果:共纳入31项研究,其中16项符合meta分析和诊断测试准确性评估的条件。荟萃分析中共有13项研究评估了对比增强超声(CEUS)对1347例转移性肝脏病变和1565例非转移性肝脏病变的诊断准确性。超声造影的敏感性和特异性分别为0.88 (95% CI: 0.82-0.92)和0.92 (95% CI: 0.84-0.96)。合并阳性似然比、阴性似然比和诊断优势比分别为11.89 (95% CI: 5.42 ~ 26.09)、0.12 (95% CI:0.08 ~ 0.19)和91.99 (95% CI: 32.15 ~ 263.17)。此外,荟萃分析的四项研究评估了对比增强术中超声(CE-IOUS)在检测664例转移性和246例非转移性肝脏病变中的诊断性能。CE-IOUS的综合敏感性和特异性分别为0.93 (95% CI: 0.82-0.97)和0.84 (95% CI: 0.65-0.93)。综合阳性似然比、阴性似然比和诊断优势比分别为5.95 (95% CI: 2.32-15.25)、0.07 (95% CI: 0.02-0.24)和77.68 (95% CI: 10.33-583.86)。结论:CE-IOUS和CEUS是诊断肝转移性病变的可靠方法。特别是CE-IOUS在识别肝转移病变方面表现出更高的准确性,表明其在临床实践中的潜在有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.00
自引率
0.00%
发文量
0
审稿时长
6 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信